Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen Memorial Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07037199, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: women only
Registered eligibility fields
Female patients aged ≥18 years. 2. Pathologically confirmed HER2-low/ultra-low, HR-positive unresectable or metastatic breast cancer:
Inclusion criterion 1
HER2-low: IHC 1+ or IHC 2+/ISH-negative;HER2-ultra-low: IHC 0 with membranous staining (>0 but <1+). HR+: ≥10% tumor cells with ER/PR nuclear staining (verified by central pathology review).
Inclusion criterion 2
Prior anti-HER2 therapy at any stage (including HER2-ADCs such as T-DM1 or T-DXd).
Exclusion criterion 1
Disease progression after endocrine therapy (ET) + CDK4/6 inhibitor in the advanced/metastatic setting.
Inclusion criterion 5
≤1 line of prior ET and ≤1 line of chemotherapy for advanced disease. 4. Measurable disease per RECIST 1.1 (including lytic/mixed bone-only metastases).
Inclusion criterion 7
Hematologic: ANC >1.5×10⁹/L; platelets >90×10⁹/L; Hb >90 g/L.
Inclusion criterion 9
Hepatic: Total bilirubin ≤ULN (≤2×ULN if Gilbert's syndrome). ALT/AST ≤1.5×ULN (≤5×ULN with liver metastases). Alkaline phosphatase ≤2.5×ULN.
Inclusion criterion 10
Renal: BUN/Cr ≤1.5×ULN.
Inclusion criterion 11
Pregnancy, lactation, or unwillingness to use effective contraception during and for 7 months post-treatment.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07037199, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
Participants must meet all of the following criteria:
- Female patients aged ≥18 years. 2. Pathologically confirmed HER2-low/ultra-low, HR-positive unresectable or metastatic breast cancer:
- HER2-low: IHC 1+ or IHC 2+/ISH-negative;HER2-ultra-low: IHC 0 with membranous staining (>0 but <1+). HR+: ≥10% tumor cells with ER/PR nuclear staining (verified by central pathology review).
- Disease stage: Recurrent/metastatic disease; locally recurrent cases must be deemed unresectable by investigators.
- Prior therapy:
- Disease progression after endocrine therapy (ET) + CDK4/6 inhibitor in the advanced/metastatic setting.
- Progression within 12 months of adjuvant ET + CDK4/6 inhibitor allowed.
- ≤1 line of prior ET and ≤1 line of chemotherapy for advanced disease. 4. Measurable disease per RECIST 1.1 (including lytic/mixed bone-only metastases).
- ECOG PS 0-1. 6. Adequate organ function (no transfusions/G-CSF within 2 weeks prior):
- Hematologic: ANC >1.5×10⁹/L; platelets >90×10⁹/L; Hb >90 g/L.
- Hepatic: Total bilirubin ≤ULN (≤2×ULN if Gilbert's syndrome). ALT/AST ≤1.5×ULN (≤5×ULN with liver metastases). Alkaline phosphatase ≤2.5×ULN.
- Renal: BUN/Cr ≤1.5×ULN.
- Cardiac: LVEF ≥50%;
- QTcF <470 ms. 7. Voluntary participation with signed informed consent.
Exclusion Criteria:
Participants will be excluded if they meet any of the following conditions:
- Prior anti-HER2 therapy at any stage (including HER2-ADCs such as T-DM1 or T-DXd).
- Significant cardiac disease, including:
- Heart failure or systolic dysfunction (LVEF <50%). 2) High-risk/treated angina or arrhythmias (e.g., Type II Mobitz II/third-degree AV block, ventricular tachycardia).
- Clinically significant valvular disease. 4) ECG-confirmed transmural myocardial infarction. 5) Uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg). 3. Interstitial lung disease (ILD)/pneumonitis:
- History of non-infectious ILD requiring steroids.
- Current ILD or suspected ILD that cannot be ruled out by imaging at screening. 4. Impaired drug absorption due to:
- Dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting oral medication intake.
- Uncontrolled third-space effusions (e.g., pleural/peritoneal effusions) not manageable by drainage.
- Pregnancy, lactation, or unwillingness to use effective contraception during and for 7 months post-treatment.
- Other exclusions:
- Severe comorbidities interfering with treatment (e.g., active HBV, pulmonary infections requiring therapy).
- Any condition deemed unsuitable by investigators.
Quoted from ClinicalTrials.gov, NCT07037199, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07037199, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.